Research output

Research output per year 2008 2010 2015 2016 2020 2021 2021

• 1285 Citations
• 12 Scopus h-Index
• 18 Article
• 8 Review article
• 1 Chapter
• 1 Comment/debate

Research output per year

Research output per year

Search results

• 2009

  Guidelines and the use of inferior vena cava filters: A review of an institutional experience

  Singh, P., Lai, H. M., Lerner, R. G., Chugh, T. & Aronow, W. S., Jan 1 2009, In: Journal of Thrombosis and Haemostasis. 7, 1, p. 65-71 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Vena Cava Filters 100%
  • Guidelines 46%
  • Pulmonary Embolism 29%
  • Venous Thromboembolism 25%
  • Venous Thrombosis 17%
  26 Scopus citations
• 2010

  Acute mesenteric vein thrombosis after laparoscopic gastric sleeve surgery for morbid obesity

  Singh, P., Sharma, M., Gandhi, K., Nelson, J. & Kaul, A., Jan 1 2010, In: Surgery for Obesity and Related Diseases. 6, 1, p. 107-108 2 p.

  Research output: Contribution to journal › Article › peer-review
  22 Scopus citations

• Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: A single-center experience

  Gandhi, K., Aronow, W. S., Desai, H., Amin, H., Sharma, M., Lai, H. M. & Singh, P., Apr 2010, In: Clinical Cardiology. 33, 4, p. 213-216 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Thrombotic Thrombocytopenic Purpura 100%
  • Myocardial Infarction 54%
  • Tachycardia 11%
  • Cardiac Arrhythmias 9%
  • Hospitalization 8%
  29 Scopus citations

• Mesenteric vein thrombosis after laproscopic gastric sleeve procedure

  Gandhi, K., Singh, P., Sharma, M., Desai, H., Nelson, J. & Kaul, A., Aug 2010, In: Journal of Thrombosis and Thrombolysis. 30, 2, p. 179-183 5 p.

  Research output: Contribution to journal › Article › peer-review
  16 Scopus citations

• Prevalence of appropriate management of diabetes mellitus in an academic general medicine clinic

  Singh, P., Aronow, W. S., Mellana, W. M. & Gutwein, A. H., Jan 1 2010, In: American journal of therapeutics. 17, 1, p. 42-45 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Diabetes Mellitus 100%
  • Medicine 91%
  • Coronary Artery Disease 62%
  • Peripheral Arterial Disease 55%
  • Stroke 34%
  3 Scopus citations

• Thiazide-induced severe hypercalcemia: A case report and review of literature

  Desai, H. V., Gandhi, K., Sharma, M., Jennine, M., Singh, P. & Brogan, M., Nov 1 2010, In: American journal of therapeutics. 17, 6, p. e234-e236

  Research output: Contribution to journal › Article › peer-review

  • Thiazides 100%
  • Hypercalcemia 79%
  • Sodium Chloride Symporter Inhibitors 27%
  • Vitamin D 19%
  • Abdominal Pain 18%
  25 Scopus citations
• 2011

  Malignant glomus tumor of kidney: The first reported case and review of literature

  Lamba, G., Rafiyath, S. M., Kaur, H., Khan, S., Singh, P., Hamilton, A. M. & Ang, D. C., Aug 2011, In: Human Pathology. 42, 8, p. 1200-1203 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Glomus Tumor 100%
  • Kidney 37%
  • Neoplasms 9%
  29 Scopus citations
• 2012

  Hepatocellular carcinoma in non-cirrhotic liver without evidence of iron overload in a patient with primary hemochromatosis. Review

  Singh, P., Kaur, H., Lerner, R. G., Patel, R., Rafiyath, S. M. & Singh Lamba, G., Mar 2012, In: Journal of gastrointestinal cancer. 43, 1, p. 36-39 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Hemochromatosis 100%
  • Iron Overload 95%
  • Hepatocellular Carcinoma 64%
  • Fibrosis 59%
  • Liver 41%
  6 Scopus citations
• 2013

  Selenium supplementation has no effect on serum glucose levels in men at high risk of prostate cancer

  Algotar, A. M., Hsu, C. H., Singh, P. & Stratton, S. P., Dec 2013, In: Journal of Diabetes. 5, 4, p. 465-470 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Selenium 100%
  • Prostatic Neoplasms 71%
  • Glucose 56%
  • Serum 40%
  • Placebos 35%
  6 Scopus citations
• 2015

  Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy

  Necchi, A., Pond, G. R., Giannatempo, P., Di Lorenzo, G., Eigl, B. J., Locke, J., Pal, S. K., Agarwal, N., Poole, A., Vaishampayan, U. N., Niegisch, G., Hussain, S. A., Singh, P., Bellmunt, J. & Sonpavde, G., Apr 1 2015, In: Clinical Genitourinary Cancer. 13, 2, p. 178-184 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Cisplatin 100%
  • Carcinoma 73%
  • Survival 40%
  • Drug Therapy 36%
  • Confidence Intervals 22%
  12 Scopus citations

• Development of PROSTVAC immunotherapy in prostate cancer

  Singh, P., Pal, S. K., Alex, A. & Agarwal, N., Aug 1 2015, In: Future Oncology. 11, 15, p. 2137-2148 12 p.

  Research output: Contribution to journal › Article › peer-review

  • PROSTVAC 100%
  • Immunotherapy 44%
  • Prostatic Neoplasms 40%
  • Prostate-Specific Antigen 34%
  • Fowlpox 30%
  27 Scopus citations
• 2016

  Laminin-binding integrin gene copy number alterations in distinct epithelial-type cancers

  Harryman, W. L., Pond, E., Singh, P., Little, A. S., Eschbacher, J. M., Nagle, R. B. & Cress, A. E., 2016, In: American Journal of Translational Research. 8, 2, p. 940-954 15 p.

  Research output: Contribution to journal › Article › peer-review

  • Gene Dosage 100%
  • Laminin 91%
  • Integrins 79%
  • Plectin 32%
  • Neoplasms 27%
  7 Scopus citations
• 2017

  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

  Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D., Hinoue, T., Laird, P. W., Hoadley, K. A., Akbani, R., Castro, M. A. A., Gibb, E. A., Kanchi, R. S., Gordenin, D. A., Shukla, S. A., Sanchez-Vega, F., Hansel, D. E., Czerniak, B. A., Reuter, V. E., Su, X. & 153 others, de Sa Carvalho, B., Chagas, V. S., Mungall, K. L., Sadeghi, S., Pedamallu, C. S., Lu, Y., Klimczak, L. J., Zhang, J., Choo, C., Ojesina, A. I., Bullman, S., Leraas, K. M., Lichtenberg, T. M., Wu, C. J., Schultz, N., Getz, G., Meyerson, M., Mills, G. B., McConkey, D. J., Albert, M., Alexopoulou, I., Ally, A., Antic, T., Aron, M., Balasundaram, M., Bartlett, J., Baylin, S. B., Beaver, A., Birol, I., Boice, L., Bootwalla, M. S., Bowen, J., Bowlby, R., Brooks, D., Broom, B. M., Bshara, W., Burks, E., Cárcano, F. M., Carlsen, R., Carvalho, A. L., Castle, E. P., Castro, P., Catto, J. W., Chesla, D. W., Chuah, E., Chudamani, S., Cortessis, V. K., Cottingham, S. L., Crain, D., Curley, E., Daneshmand, S., Demchok, J. A., Dhalla, N., Djaladat, H., Eckman, J., Egea, S. C., Engel, J., Felau, I., Ferguson, M. L., Gardner, J., Gastier-Foster, J. M., Gerken, M., Gomez-Fernandez, C. R., Harr, J., Hartmann, A., Herbert, L. M., Ho, T. H., Holt, R. A., Hutter, C. M., Jones, S. J. M., Jorda, M., Kahnoski, R. J., Kasaian, K., Kwiatkowski, D. J., Lai, P. H., Lane, B. R., Lerner, S. P., Liu, J., Lolla, L., Lotan, Y., Lucchesi, F. R., Ma, Y., Machado, R. D., Maglinte, D. T., Mallery, D., Marra, M. A., Martin, S. E., Mayo, M., Meraney, A., Moinzadeh, A., Moore, R. A., Mora Pinero, E. M., Morris, S., Morrison, C., Mungall, A. J., Myers, J. B., Naresh, R., O'Donnell, P. H., Parekh, D. J., Parfitt, J., Paulauskis, J. D., Sekhar Pedamallu, C., Penny, R. J., Pihl, T., Porten, S., Quintero-Aguilo, M. E., Ramirez, N. C., Rathmell, W. K., Rieger-Christ, K., Saller, C., Salner, A., Sandusky, G., Scapulatempo-Neto, C., Schein, J. E., Schuckman, A. K., Shelton, C., Shelton, T., Simko, J., Singh, P., Sipahimalani, P., Smith, N. D., Sofia, H. J., Sorcini, A., Stanton, M. L., Steinberg, G. D., Stoehr, R., Su, X., Sullivan, T., Sun, Q., Tam, A., Tarnuzzer, R., Tarvin, K., Taubert, H., Thiessen, N., Thorne, L., Tse, K., Tucker, K., Van Den Berg, D. J., van Kessel, K. E., Wach, S., Wan, Y., Wang, Z., Weinstein, J. N., Weisenberger, D. J., Wise, L., Wong, T., Wu, Y., Yang, L., Zach, L. A., Zenklusen, J. C., Zhang, J., Zmuda, E. & Zwarthoff, E. C., Oct 19 2017, In: Cell. 171, 3, p. 540-556.e25

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Urinary Bladder Neoplasms 100%
  • Cluster Analysis 93%
  • MicroRNA 63%
  • Muscles 62%
  • Mutation 44%
  738 Scopus citations
• 2018

  Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma

  Chesney, J., Puzanov, I., Collichio, F., Singh, P., Milhem, M. M., Glaspy, J., Hamid, O., Ross, M., Friedlander, P., Garbe, C., Logan, T. F., Hauschild, A., Lebbé, C., Chen, L., Kim, J. J., Gansert, J., Andtbacka, R. H. I. & Kaufman, H. L., Jun 10 2018, In: Journal of Clinical Oncology. 36, 17, p. 1658-1667 10 p.

  Research output: Contribution to journal › Article › peer-review

  • talimogene laherparepvec 100%
  • Ipilimumab 76%
  • Melanoma 45%
  • Safety 31%
  250 Scopus citations
• 2019

  Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma

  Chesney, J., Puzanov, I., Collichio, F., Milhem, M. M., Hauschild, A., Chen, L., Sharma, A., Garbe, C., Singh, P. & Mehnert, J. M., Aug 27 2019, In: British journal of cancer. 121, 5, p. 417-420 4 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • talimogene laherparepvec 100%
  • Ipilimumab 76%
  • Melanoma 45%
  • Tumor Burden 13%
  7 Scopus citations
• 2020

  PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study

  Petrylak, D. P., Vogelzang, N. J., Chatta, K., Fleming, M. T., Smith, D. C., Appleman, L. J., Hussain, A., Modiano, M., Singh, P., Tagawa, S. T., Gore, I., McClay, E. F., Mega, A. E., Sartor, A. O., Somer, B., Wadlow, R., Shore, N. D., Olson, W. C., Stambler, N., DiPippo, V. A. & 1 others, Israel, R. J., Jan 1 2020, In: Prostate. 80, 1, p. 99-108 10 p.

  Research output: Contribution to journal › Article › peer-review

  • abiraterone 100%
  • MDV 3100 96%
  • Castration 72%
  • Prostate-Specific Antigen 67%
  • Prostatic Neoplasms 52%
  7 Scopus citations
• 2021

  Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer

  Velez, M. G., Kosiorek, H. E., Egan, J. B., McNatty, A. L., Riaz, I. B., Hwang, S. R., Stewart, G. A., Ho, T. H., Moore, C. N., Singh, P., Sharpsten, R. K., Costello, B. A. & Bryce, A. H., 2021, (Accepted/In press) In: Prostate Cancer and Prostatic Diseases.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tumor Suppressor Genes 100%
  • Prostatic Neoplasms 80%
  • Hormones 71%
  • Progression-Free Survival 61%
  • Abiraterone Acetate 26%

• Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration

  Ravi, P., Pond, G. R., Diamantopoulos, L. N., Su, C., Alva, A., Jain, R. K., Skelton, W. P., Gupta, S., Tward, J. D., Olson, K. M., Singh, P., Grunewald, C. M., Niegisch, G., Lee, J. L., Gallina, A., Bandini, M., Necchi, A., Mossanen, M., McGregor, B. A., Curran, C. & 2 others, Grivas, P. & Sonpavde, G. P., Nov 2021, In: BJU international. 128, 5, p. 607-614 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Urinary Bladder Neoplasms 100%
  • Cystectomy 78%
  • Vinblastine 63%
  • Muscles 62%
  • Cisplatin 62%